Vitamin E succinate with multiple functions: A versatile agent in nanomedicine-based cancer therapy and its delivery strategies

Int J Pharm. 2021 May 1:600:120457. doi: 10.1016/j.ijpharm.2021.120457. Epub 2021 Mar 4.

Abstract

Vitamin E succinate (VES), a succinic acid ester of vitamin E, is one of the most effective anticancer compounds of the vitamin E family. VES can inhibit tumor growth by multiple pathways mainly involve tumor proliferation inhibition, apoptosis induction, and metastasis prevention. More importantly, the mitochondrial targeting and damaging property of VES endows it with great potential in exhibiting synergetic effect with conventional chemotherapeutic drugs and overcoming multidrug resistance (MDR). Given the lipophilicity of VES that hinders its bioavailability and therapeutic activity, nanotechnology with multiple advantages has been widely explored to deliver VES and opened up new avenues for its in vivo application. This review aims to introduce the anticancer mechanisms of VES and summarize its delivery strategies using nano-drug delivery systems. Specifically, VES-based combination therapy for synergetic anticancer effect, MDR-reversal, and oral chemotherapy improvement are highlighted. Finally, the challenges and perspectives are discussed.

Keywords: Cancer therapy; MDR-reversal; Mitochondrial targeting; Nano-carriers; Synergistic effects; Vitamin E succinate.

Publication types

  • Review

MeSH terms

  • Antineoplastic Agents* / pharmacology
  • Apoptosis
  • Drug Resistance, Multiple
  • Humans
  • Nanomedicine
  • Neoplasms* / drug therapy
  • Vitamin E / pharmacology
  • alpha-Tocopherol / pharmacology

Substances

  • Antineoplastic Agents
  • Vitamin E
  • alpha-Tocopherol